← Back to patent-cliff list
Amlodipine Oral Solution (Brillian Pharma)
Tier C — Watch / tradeAmlodipine Oral Solution (Brillian Pharma)
Brillian Pharma Inc
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：VDCCs
Brand：Sdamlo
Indications (approved)：Hypertension, Coronary artery lesion
Regional status
US
Approved
2025-07-24
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amlodipine Oral Solution (Brillian Pharma)?
Approved indications include: Hypertension, Coronary artery lesion.
When does the Amlodipine Oral Solution (Brillian Pharma) patent expire?
No public expiry year is available for Amlodipine Oral Solution (Brillian Pharma) yet; this page updates once verified.
How do I get a quote for Amlodipine Oral Solution (Brillian Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01